

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Allenspach et al.)	GROUP ART UNIT:	1617
)		
SERIAL NO.:	10/647,501)	CONFIRMATION NO.:	2375
)		
EXAMINER:	Claytor)	ATTORNEY DOCKET NO.:	01139/3/US
)		
FILED:	August 25, 2003)		(PC 27523)
)		
TITLE:	PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE			

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 5, 2006
(First Business day after September 4, 2006)

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office action of August 4, 2006 in the above-identified application, please consider the following remarks.

Claims 1-29 are pending, and are subject to restriction between Group I (claims 1-23), Group II (claims 24-27), Group III (claim 28), and Group IV (claim 29).

Applicants elect the invention of Group I, and reserve the right to file one or more divisional applications directed to the non-elected subject matter.

Further to the request under 35 U.S.C. §121, requiring election of species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable, Applicants elect valdecoxib as the drug of low water solubility and cyclooxygenase-2 inhibitory drug and corn starch as the pregelatinized starch

Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,



Patricia K. Fitzsimmons
Registration No. 52,894

Pharmacia Corporation
Post Office Box 1027
St. Louis, MO 63006
Telephone: 314.274.1490
Facsimile: 314.274.9095

via EFS